What makes PsO systemic and multifactorial?
PsO involves more than visible plaques: genetics, immune cells and skin cells interact in a self-sustaining loop.
Dendritic cells release IL-23. Th17 cells respond with IL-17 and IL-22. Keratinocytes then proliferate and release more inflammatory signals, which recruit more immune cells.
- Systemic. Inflammation is not confined to the skin; PsO is associated with joint, cardiometabolic and mood disorders.
- Multifactorial. Genetic risk, immune activity and environmental triggers all contribute.
- Interconnected. IL-23, IL-12 and type I interferon pathways overlap rather than act alone.
What does ongoing disease burden look like?
Burden includes physical symptoms, emotional impact and associated conditions.
Physical symptoms
Itch, pain, scaling, cracking and bleeding can persist and flare unpredictably.
Emotional impact
Visible disease is linked to stigma, self-consciousness, anxiety and depression.
Daily life
Sleep, work, intimacy and social activities are often affected.
Conditions associated with PsO
- Psoriatic arthritis
- Cardiovascular disease
- Metabolic syndrome and obesity
- Depression and anxiety
What unmet needs remain?
Many patients are managed well, yet gaps remain.
- Not every patient reaches, or keeps, clear skin with current options.
- Patients often move through several therapies over time.
- Treatment choices weigh efficacy against safety, tolerability and monitoring.
- Many patients and HCPs want effective options that fit easily into daily life.
Quick answers
Is PsO only a skin condition?
No. PsO is a chronic, immune-mediated inflammatory disease with skin manifestations, and it is associated with conditions such as psoriatic arthritis and cardiometabolic disease.
Why do many patients still have unmet needs?
Not every patient reaches or maintains clear skin with current options, and treatment decisions must balance efficacy with safety and tolerability.
Which cells and signals drive a psoriatic plaque?
Dendritic cells release IL-23, Th17 cells release IL-17 and IL-22, and keratinocytes respond by proliferating and releasing more inflammatory mediators.